FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167180523> ?p ?o ?g. }

• W3167180523 endingPage "5990" @default.
• W3167180523 startingPage "5990" @default.
• W3167180523 abstract "Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resistance development, combination approaches are warranted. Herein, we applied a combined regimen with an α-PD-L1 antibody and gemcitabine in a preclinical tumor model to activate endogenous antitumor immune responses. Mlh1−/− mice with established gastrointestinal tumors received the α-PD-L1 antibody (clone 6E11; 2.5 mg/kg bw, i.v., q2wx3) and gemcitabine (100 mg/kg bw, i.p., q4wx3) in mono- or combination therapy. Survival and tumor growth were recorded. Immunological changes in the blood were routinely examined via multi-color flow cytometry and complemented by ex vivo frameshift mutation analysis to identify alterations in Mlh1−/−-tumor-associated target genes. The combined therapy of α-PD-L1 and gemcitabine prolonged median overall survival of Mlh1−/− mice from four weeks in the untreated control group to 12 weeks, accompanied by therapy-induced tumor growth inhibition, as measured by [18F]-FDG PET/CT. Plasma cytokine levels of IL13, TNFα, and MIP1β were increased and also higher than in mice receiving either monotherapy. Circulating splenic and intratumoral myeloid-derived suppressor cells (MDSCs), as well as M2 macrophages, were markedly reduced. Besides, residual tumor specimens from combi-treated mice had increased numbers of infiltrating cytotoxic T-cells. Frameshift mutations in APC, Tmem60, and Casc3 were no longer detectable upon treatment, likely because of the successful eradication of single mutated cell clones. By contrast, novel mutations appeared. Collectively, we herein confirm the safe application of combined chemo-immunotherapy by long-term tumor growth control to prevent the development of resistance mechanisms." @default.
• W3167180523 created "2021-06-22" @default.
• W3167180523 creator A5012794413 @default.
• W3167180523 creator A5033484349 @default.
• W3167180523 creator A5038809102 @default.
• W3167180523 creator A5045384350 @default.
• W3167180523 creator A5051060247 @default.
• W3167180523 creator A5055468693 @default.
• W3167180523 creator A5064242864 @default.
• W3167180523 creator A5077750770 @default.
• W3167180523 creator A5083831443 @default.
• W3167180523 creator A5087351196 @default.
• W3167180523 date "2021-06-01" @default.
• W3167180523 modified "2023-09-29" @default.
• W3167180523 title "Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors" @default.
• W3167180523 cites W1839029088 @default.
• W3167180523 cites W2010480908 @default.
• W3167180523 cites W2024397742 @default.
• W3167180523 cites W2071069178 @default.
• W3167180523 cites W2131348295 @default.
• W3167180523 cites W2132834292 @default.
• W3167180523 cites W2140737233 @default.
• W3167180523 cites W2145994992 @default.
• W3167180523 cites W2176093842 @default.
• W3167180523 cites W2282962877 @default.
• W3167180523 cites W2464620827 @default.
• W3167180523 cites W2477016117 @default.
• W3167180523 cites W2537295025 @default.
• W3167180523 cites W2538415730 @default.
• W3167180523 cites W2565479307 @default.
• W3167180523 cites W2606494852 @default.
• W3167180523 cites W2620853632 @default.
• W3167180523 cites W2735646232 @default.
• W3167180523 cites W2736908520 @default.
• W3167180523 cites W2769168515 @default.
• W3167180523 cites W2772576480 @default.
• W3167180523 cites W2788371883 @default.
• W3167180523 cites W2788898141 @default.
• W3167180523 cites W2801311742 @default.
• W3167180523 cites W2806358230 @default.
• W3167180523 cites W2808333550 @default.
• W3167180523 cites W2884824167 @default.
• W3167180523 cites W2897460617 @default.
• W3167180523 cites W2904450979 @default.
• W3167180523 cites W2915738743 @default.
• W3167180523 cites W2916552355 @default.
• W3167180523 cites W2948588034 @default.
• W3167180523 cites W2970410478 @default.
• W3167180523 cites W2971309637 @default.
• W3167180523 cites W2977522239 @default.
• W3167180523 cites W2981285743 @default.
• W3167180523 cites W2984359187 @default.
• W3167180523 cites W3007076179 @default.
• W3167180523 cites W3011009916 @default.
• W3167180523 cites W3014546376 @default.
• W3167180523 cites W3014605876 @default.
• W3167180523 cites W3037477427 @default.
• W3167180523 cites W3091949069 @default.
• W3167180523 cites W3094157886 @default.
• W3167180523 cites W3095618804 @default.
• W3167180523 cites W3110528877 @default.
• W3167180523 cites W3113745434 @default.
• W3167180523 cites W3116093609 @default.
• W3167180523 cites W3126377118 @default.
• W3167180523 cites W3126407524 @default.
• W3167180523 cites W3126685839 @default.
• W3167180523 cites W3132863042 @default.
• W3167180523 cites W3135703768 @default.
• W3167180523 cites W3158668760 @default.
• W3167180523 doi "https://doi.org/10.3390/ijms22115990" @default.
• W3167180523 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8199186" @default.
• W3167180523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34206051" @default.
• W3167180523 hasPublicationYear "2021" @default.
• W3167180523 type Work @default.
• W3167180523 sameAs 3167180523 @default.
• W3167180523 citedByCount "12" @default.
• W3167180523 countsByYear W31671805232021 @default.
• W3167180523 countsByYear W31671805232022 @default.
• W3167180523 countsByYear W31671805232023 @default.
• W3167180523 crossrefType "journal-article" @default.
• W3167180523 hasAuthorship W3167180523A5012794413 @default.
• W3167180523 hasAuthorship W3167180523A5033484349 @default.
• W3167180523 hasAuthorship W3167180523A5038809102 @default.
• W3167180523 hasAuthorship W3167180523A5045384350 @default.
• W3167180523 hasAuthorship W3167180523A5051060247 @default.
• W3167180523 hasAuthorship W3167180523A5055468693 @default.
• W3167180523 hasAuthorship W3167180523A5064242864 @default.
• W3167180523 hasAuthorship W3167180523A5077750770 @default.
• W3167180523 hasAuthorship W3167180523A5083831443 @default.
• W3167180523 hasAuthorship W3167180523A5087351196 @default.
• W3167180523 hasBestOaLocation W31671805231 @default.
• W3167180523 hasConcept C121608353 @default.
• W3167180523 hasConcept C126322002 @default.
• W3167180523 hasConcept C151730666 @default.
• W3167180523 hasConcept C203014093 @default.
• W3167180523 hasConcept C2776999253 @default.
• W3167180523 hasConcept C2777701055 @default.
• W3167180523 hasConcept C2778326572 @default.

• next